{
  "actions": [
    {
      "acted_at": "2012-04-18",
      "action_code": "Intro-H",
      "references": [],
      "text": "Introduced in House",
      "type": "action"
    },
    {
      "acted_at": "2012-04-18",
      "action_code": "H11100",
      "committees": [
        "HSIF"
      ],
      "references": [],
      "status": "REFERRED",
      "text": "Referred to the House Committee on Energy and Commerce.",
      "type": "referral"
    },
    {
      "acted_at": "2012-04-20",
      "action_code": "",
      "committees": [
        "HSIF"
      ],
      "references": [],
      "text": "Referred to the Subcommittee on Health.",
      "type": "referral"
    }
  ],
  "amendments": [],
  "bill_id": "hr4384-112",
  "bill_type": "hr",
  "by_request": false,
  "committee_reports": [],
  "committees": [
    {
      "activity": [
        "referral"
      ],
      "committee": "House Energy and Commerce",
      "committee_id": "HSIF"
    },
    {
      "activity": [
        "referral"
      ],
      "committee": "House Energy and Commerce",
      "committee_id": "HSIF",
      "subcommittee": "Subcommittee on Health",
      "subcommittee_id": "14"
    }
  ],
  "congress": "112",
  "cosponsors": [
    {
      "bioguide_id": "B001259",
      "district": "1",
      "name": "Braley, Bruce L.",
      "original_cosponsor": true,
      "sponsored_at": "2012-04-18",
      "state": "IA",
      "title": "Rep.",
      "withdrawn_at": null
    }
  ],
  "enacted_as": null,
  "history": {
    "active": false,
    "awaiting_signature": false,
    "enacted": false,
    "vetoed": false
  },
  "introduced_at": "2012-04-18",
  "number": "4384",
  "official_title": "To permit manufacturers of generic drugs to provide additional warnings with respect to such drugs in the same manner that the Food and Drug Administration allows brand names to do so.",
  "popular_title": null,
  "related_bills": [
    {
      "bill_id": "s2295-112",
      "identified_by": "CRS",
      "reason": "related",
      "type": "bill"
    }
  ],
  "short_title": "Patient Safety and Drug Labeling Improvement Act",
  "sponsor": {
    "bioguide_id": "V000128",
    "district": "8",
    "name": "Van Hollen, Chris",
    "state": "MD",
    "title": "Rep.",
    "type": "person"
  },
  "status": "REFERRED",
  "status_at": "2012-04-18",
  "subjects": [
    "Consumer affairs",
    "Drug safety, medical device, and laboratory regulation",
    "Health",
    "Health information and medical records",
    "Prescription drugs"
  ],
  "subjects_top_term": "Health",
  "summary": {
    "as": "Introduced in House",
    "asOf": "2012-04-18",
    "date": "2012-05-15T17:21:37Z",
    "text": "Patient Safety and Drug Labeling Improvement Act - Amends the Federal Food, Drug, and Cosmetic Act to allow the holder of an approved abbreviated new drug application (generic drug approval) to change the labeling of a drug so approved in the same manner authorized by regulation for the holder of an approved new drug application.\n\nAllows conforming changes to be ordered to the labeling of the equivalent listed drug and each drug approved under the abbreviated new drug application process that corresponds to such listed drug."
  },
  "titles": [
    {
      "as": "introduced",
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "Patient Safety and Drug Labeling Improvement Act",
      "type": "short"
    },
    {
      "as": null,
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "Patient Safety and Drug Labeling Improvement Act",
      "type": "display"
    },
    {
      "as": "introduced",
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "To permit manufacturers of generic drugs to provide additional warnings with respect to such drugs in the same manner that the Food and Drug Administration allows brand names to do so.",
      "type": "official"
    }
  ],
  "updated_at": "2019-11-15T21:18:13Z",
  "url": "https://www.govinfo.gov/bulkdata/BILLSTATUS/112/hr/BILLSTATUS-112hr4384.xml"
}